Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > SHISEIDO WILL COMMERCIALIZE RCH-01

<< Previous

Bullboard Posts

Next >>

Comment by MetzGERon Oct 18, 2023 6:16am

68 Views

Post# 35688455

RE:RE:SHISEIDO WILL COMMERCIALIZE RCH-01

With your Post you do Everything for your predictions coming true.

But answer me One simple question:
what will be Shiseidos strategy to commercialize RCH-01 Without having the worldwide rights which Are in the Hand of Replicel ?

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec